CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two types of secondary acute myeloid leukemia (AML). Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the safety profile of this exciting drug.
Liposomal chemotherapy CPX-351: safety profile
